Navigation Links
Selexis Now Offering Rapid-Development of Human Cell Line With FDA Approval Pedigree
Date:7/16/2008

New contract service offering rapid development of high performance HEK293 (human) production cell lines enabled by Selexis Genetic Elements(TM) and

Selexis SURE(TM) Cell Line Development program

GENEVA, July 16 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering DNA based technologies and supportive services to enable significantly improved drug discovery, development, and cGMP production of biologics, announced today it has partnered with the National Research Counsel of Canada's Biological Research Institute (NRC-BRI) to offer the NRC-BRI HEK293 cell technologies for the contract development of high-performance stable human cell lines enabled by the Selexis Genetic Element(TM) and Selexis SURE Cell Line Development(SM) Services.

HEK293 cells are the most widely used HUMAN cell line in biotechnology industry and the ONLY human cell line used for the bioproduction of an FDA approved biopharmaceutical drug.

Xigrils(R), a recombinant form of human Activated Protein C, is marketed by Eli Lilly and Company for the treatment of severe sepsis. Xigrils(R) was approved by US-FDA in November of 2001 and is produced using HEK293 cells.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"Partnering with the NCR-BRI to offer their well characterized human cell line is a perfect complement to our well developed and proven CHO platform, especially considering the fact that HEK293 cells have already been approved for the production of a recombinant protein drug."

"For over a decade Dr. Amine Kamen and his team of researchers at the BRI have done an outstanding job of developing their HEK293 program for large scale production purposes and now Selexis has the opportunity to make it more widely available with improved performance characteristics using our Selexis Genetic Element(TM) technology and our Selexis SURE Cell Line Development(SM) Services."

"This partnership will further reinf
'/>"/>

SOURCE Selexis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Eularis Announces New Corporate Name and Expanded Product Offerings
3. Healthcare Realty Trust Announces Public Offering of Common Stock
4. FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
5. Volcano Corporation Announces Proposed Public Offering of Common Stock
6. Highlands Acquisition Corp. Completes Initial Public Offering
7. AKELA Pharma Inc. announces U.S. public offering and proposed listing
8. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
9. Akron-Canton Airport offering flu shot clinic for 90 days
10. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Illinois (PRWEB) April 24, 2015 Multi ... includes septic tank pumping ( http://www.zeitersseptics.com/multi-customer-discount.html ) of 1000-1500 ... to start the program. This does not include any ... applicable. Save $25-$65 per person. If someone is part ... or two tanks totaling approximately 2500 gallons or more, ...
(Date:4/24/2015)... The Fastest Fat Loss Week Ever, released ... of the Xtreme Fat Loss Diet, has been causing a ... blueprint that claims to help one lose belly fat in ... Stevenson, prompting an investigative review. , "Our Fastest Fat ... years researching and experimenting with these methods on their clients ...
(Date:4/24/2015)... April 24, 2015 The first step ... the mind. , For meditation and yoga teacher Stine ... have been invaluable tools that allow her to experience ... She has been a teacher since 2006, and through ... inner state of being. , “I love sharing this ...
(Date:4/24/2015)... Integrative Therapeutics has introduced two new ... cognition. , A unique combination of herbs and ... Flavonoid Complex apart from other antioxidant supplements. This ... support antioxidation versus the use of single or ... extract, Resveratrol, Alpha-Glycosyl Isoquercitrin, and Coenzyme Q10 with ...
(Date:4/24/2015)... 24, 2015 Insuranceautoquote.info has released a ... insurance premiums . , Lowering auto insurance prices ... to simply find better offers for their financial budget. ... it does not require any registration. , Comparing ... There are multiple agencies that sell coverage and this ...
Breaking Medicine News(10 mins):Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 2Health News:Zeiter's Septics Inc. Offers Multi Customer Septic Tank Cleaning Program in Cook, Putnam & Will Counties in May 2015 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 2Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 3Health News:Integrative Therapeutics Introduces Two ProThrivers™ Wellness Supplements with Specialty Ingredients from Kyowa Hakko USA 4Health News:Car Insurance Quotes Can Help Drivers Lower Their Premiums 2
... PALM SPRINGS, Calif., Aug. 6 Desert Oasis Healthcare, an ... highlighted in a USA Today story discussing the country,s most ... Medicare Plan Obama calls ,wasteful," Desert Oasis is described as ... and reduce hospital readmissions." , , (Photo: ...
... 6: Numbers were impressive at June,s CPhI China ... China - which together form Asia ... equipment communities. , , Staged by UBM at Shanghai,s ... 1,651 exhibitors from 17 countries and welcomed nearly 23,700 visits. , ...
... UV exposure associated with skin inflammation in study of ... sun,s ultraviolet (UV) rays may trigger certain types of ... , "This study found that women who lived in ... developed an autoimmune muscle disease called myositis were more ...
... , , SAN DIEGO, Aug. 6 ... focused on the treatment of obesity, today announced unaudited financial results for ... Three Months Ended June 30, 2009 , As of ... and an additional $37.4 million in investment securities, available-for-sale. In July ...
... , EATONTOWN, N.J., Aug. 6 Osteotech, Inc. ... of biologic products for regenerative healing, announced today that its management ... Global Growth Conference at the InterContinental Hotel in Boston on Thursday, ... A live, listen-only webcast of the presentation will be available ...
... , , , ... , Twitter was shut down Thursday morning August 6 due to a denial of service ... at Integralis, can discuss: , , - Why are Web 2.0 ... is more like a human brain than a simple website. Its users are within ...
Cached Medicine News:Health News:Desert Oasis Healthcare Featured in USA Today 2Health News:Desert Oasis Healthcare Featured in USA Today 3Health News:Desert Oasis Healthcare Featured in USA Today 4Health News:China Pharma Events Keep Growing For UBM 2Health News:China Pharma Events Keep Growing For UBM 3Health News:Sunlight May Cause Rash in Autoimmune Disease 2Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 2Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 3Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 4Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 5Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 6Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 7Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 8Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 9Health News:Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results 10Health News:Integralis Expert Resource Available to Discuss Twitter Denial of Service Attack and Web 2.0 Security 2
(Date:4/24/2015)... 24, 2015   Vestagen Technical Textiles, Inc. ... , has recently received two notable innovation awards. The ... that recognizes innovations with potential to create a positive ... in New York City , VESTEX ... "Protection & Safety" category. The awards honor excellence in ...
(Date:4/24/2015)... , Apr. 24, 2015 Research and ... announced the addition of the "Lab ... tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station) & End User ... Global Forecast to 2020" report to ... accessories market is expected to reach $504.7 ...
(Date:4/24/2015)... , April 24, 2015 Hi-Tech ... that such was not the product of reliable scientific ... a reliable basis for allegations of adulteration. The ... on a false premise, or misguided hope, that ... these studies are contradicted by multiple other studies ...
Breaking Medicine Technology:VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6
... WIRE)--Jun 7, 2007 - Inovio Biomedical,Corporation (AMEX:INO), ... cancers and infectious diseases and a novel ... today that the,company's partner, Vical Incorporated, presented ... subjects from an ongoing Phase I,clinical trial ...
... clinically meaningful pain relief within 5,minutes of dosing ... 2007 - Archimedes Pharma Ltd,("Archimedes"), a European specialty ... Phase II study of Nasalfent(r),an innovative fentanyl citrate ... convenient treatment for breakthrough cancer,pain. Data were presented ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... stone manipulation and removal in the urinary tract. ... retain its shape following extreme torsion. The unique ... allowing the basket to open at the base ... tipless design reduces the likelihood of mucosal damage ...
Medicine Products: